RESTARI

Device, Pharmaceutical, Gene Therapy Solutions for Severe Diseases

“(Acute Kidney Injury Treatment) Huge field with no therapy…we know when it is coming but can do nothing about it."

Past President of American Academy of Nephrology

RESTARI: Innovation for underserved severe kidney diseases and other life threatening diseases

Breakthrough devices for:
- Treating acute kidney injury
- Renal gene therapy delivery
- Cancer and renal function biopsy
Small molecule and gene therapy programs targeting polycystic kidney disease

Technology Platforms

With expected launches starting soon and continuing into the next decade, our portfolio is carefully selected to help people win their fight with a special emphasis on biopsy dependent informatics and underserved renal diseases and biopsy.

Acute Kidney Injury

Acute kidney injury (AKI) occurs when low blood pressure causes blood cells to aggregate in renal capillaries and reduce blood flow. This reduction triggers inflammation, impedes nutrient supply and impairs filtration by the kidney.

AKI can cause permanent kidney damage leading to dialysis, chronic kidney disease and even death.

Currently, there are no therapies for AKI.

RESTARI is in late-stage clinical development of the first device to stop and reverse AKI when it first occurs.

Polycystic Kidney Disease

Polycystic Kidney Disease (PKD) is a genetic disease that causes progressive kidney damage. RESTARI is working to develop a well-tolerated, once daily tablet intended to shrink cyst size and slow their growth. RESTARI is in the discovery phase of a gene therapy treatment meant to repair the mutation that causes PKD.

Superior Biopsy Samples for Cancer Detection and Kidney Disease Analysis

RESTARI is preparing to launch the MorCor full core biopsy device and complementary technologies with a special emphasis on breast care.

The MorCor device is designed to deliver samples of superior quality and size to enable better informed clinical decision making.

RESTARI's treatments are intended for millions of people every year in the U.S. alone.

800,000

People with AKI

1,300,000

Breast biopsies

160,000

People with PKD

60,000

Kidney biopsies